NEWTON, Mass.--(BUSINESS WIRE)--March 8, 2006--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has filed a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) for a single pivotal Phase 3 trial in advanced non-small cell lung cancer, for its lead product NOV-002 in combination with first-line chemotherapy. The primary endpoint of the trial is overall survival.
